In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 3, 2007, Pages 1112-1114

  Livermore, David M ^a   Warner, Marina ^a   Mushtaq, Shazad ^a   North, Sarah ^a,b   Woodford, Neil ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b VETERINARY LABORATORIES AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; OXAZOLIDINONE DERIVATIVE; RNA 23S; RWJ 416457; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GENE MUTATION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MUTATION; OXAZOLIDINONES; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAPHYLOCOCCUS AUREUS;

EID: 33847649581     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01347-06     Document Type: Article

References (11)

1. Foleno, B. D., D. Abbanat, R. M. Goldschmidt, R. K. Flamm, S. D. Paget, G. C. Webb, E. Wira, M. J. Macielag, and K. Bush. 2007. In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Antimicrob. Agents Chemother. 51:361-365.
2. Johnson, A. P., H. Aucken, S. Cavendish, M. Ganner, M. J. Wale, W. Warner, D. M. Livermore, B. D. Cookson, et al. 2001. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J. Antimicrob. Chemother. 48:144.
3. Livermore, D. M. 2003. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51(Suppl. 2):ii9-ii16.
4. Meka, V. G., and H. S. Gold. 2004. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39:1010-1015.
5. National Committee for Clinical Laboratory Standards. 2003. Methods of dilution antimicrobial susceptibility testing of bacteria that grow aerobically, 6th ed. Approved standard M07-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
6. O'Neill, A. J., and I. Chopra. 2002. Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low. J. Antimicrob. Chemother. 50:161-169.
7. Reynolds, R., N. Potz, M. Colman, A. Williams, D. Livermore, and A. MacGowan. 2004. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J. Antimicrob. Chemother. 53:1018-1032.
8. Sinclair, A., C. Arnold, and N. Woodford. 2003. Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in enterococci. Antimicrob. Agents Chemother. 47:3620-3622.
9. Weigelt, J., K. Itani, D. Stevens, W. Lau, M. Dryden, and C. Knirsch. 2005. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49:2260-2266.
10. Wilcox, M. H. 2003. Efficacy of linezolid versus comparator therapies in Gram-positive infections. J. Antimicrob. Chemother. 51(Suppl. 2):ii27-ii35.
11. Wunderink, R. G., J. Rello, S. K. Cammarata, R. V. Croos-Dabrera, and M. H. Kollef. 2003. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789-1797.